Drug intelligence / Profile preview

USM105

Development stage: Unknown
Lead developer: Uscare Pharm
Modality: Small Molecules

Overview

USM105 is a research-stage oncology asset developed by Uscare Pharm, a biotechnology company specializing in ultrasound-responsive therapeutic technologies. It is categorized within the company's pipeline under both 'Material Innovation' and 'Platform Innovation.' While specific molecular details are limited, USM105 is designed as a specialized material or sonosensitizer intended to enhance the precision and efficacy of cancer treatments, potentially through ultrasound-mediated drug delivery or sonodynamic therapy (SDT). The program aims to leverage ultrasound waves to trigger localized therapeutic effects, thereby improving the therapeutic index of anti-cancer agents and minimizing systemic toxicity.

Other names: USM105 (Material)

Beyond the preview

Go deeper on USM105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on USM105.

Explore the full profile